Structure Therapeutics Inc ADR Financials
This page shows Structure Therapeutics Inc ADR (GPCR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Structure Therapeutics operates as an equity-funded development platform, pairing a cash-heavy balance sheet with rapidly rising R&D burn.
From FY2023 to FY2025, financing inflows reached about$1.73B , far above cumulative operating cash burn of about-$418M . That is why cash could rise to$800M even as FY2025 free cash flow fell to-$225.8M : the business is turning capital raises into research runway, not funding itself from operations.
R&D expense more than doubled from
Cash burn is mostly operating burn, not heavy reinvestment in physical assets: FY2025 capex was just
Financial Health Signals
Structure Therapeutics Inc ADR does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Structure Therapeutics Inc ADR passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Structure Therapeutics Inc ADR reported a net loss of $141.2M while operations used $222.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Structure Therapeutics Inc ADR's EBITDA was -$175.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 11.4% from the prior year.
Structure Therapeutics Inc ADR reported -$141.2M in net income in fiscal year 2025. This represents a decrease of 15.2% from the prior year.
Structure Therapeutics Inc ADR earned -$0.80 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 2.6% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Structure Therapeutics Inc ADR recorded an outflow of $225.8M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 91.5% from the prior year.
Structure Therapeutics Inc ADR held $799.6M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Structure Therapeutics Inc ADR's ROE was -9.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 4.9 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Structure Therapeutics Inc ADR invested $225.3M in research and development in fiscal year 2025. This represents an increase of 107.0% from the prior year.
Structure Therapeutics Inc ADR invested $3.6M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 180.2% from the prior year.
Not reported for fiscal year 2025.
GPCR Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| R&D Expenses | N/A | $225.3M+107.0% | $108.8M+55.2% | $70.1M+93.7% | $36.2M |
| SG&A Expenses | N/A | $61.6M+24.6% | $49.4M+51.2% | $32.7M+99.6% | $16.4M |
| Operating Income | N/A | -$176.6M-11.6% | -$158.2M-54.0% | -$102.8M-95.5% | -$52.6M |
| Income Tax | N/A | $515K+66.1% | $310K+31.4% | $236K+1288.2% | $17K |
| Net Income | N/A | -$141.2M-15.2% | -$122.5M-36.7% | -$89.6M-74.6% | -$51.3M |
| EPS (Diluted) | — | -$0.80-2.6% | -$0.78+3.7% | -$0.81 | -$5.51 |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
GPCR Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|
| Total Assets | $1.6B+75.3% | $903.3M+87.4% | $482.0M+392.6% | $97.8M |
| Current Assets | $1.6B+76.2% | $891.2M+88.2% | $473.6M+408.8% | $93.1M |
| Cash & Equivalents | $799.6M+371.7% | $169.5M+30.6% | $129.8M+397.5% | $26.1M |
| Total Liabilities | $67.5M+75.5% | $38.5M+32.5% | $29.1M-86.4% | $213.0M |
| Current Liabilities | $63.3M+75.7% | $36.0M+45.6% | $24.7M+90.2% | $13.0M |
| Total Equity | $1.5B+75.3% | $864.8M+90.9% | $453.0M+493.4% | -$115.1M |
| Retained Earnings | -$470.3M-42.9% | -$329.1M-59.3% | -$206.6M-76.6% | -$117.0M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
GPCR Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$220.3M | -$222.2M-90.5% | -$116.6M-46.7% | -$79.5M-72.4% | -$46.1M |
| Capital Expenditures | $4.2M | $3.6M+180.2% | $1.3M-40.5% | $2.2M+1298.1% | $155K |
| Free Cash Flow | -$224.6M | -$225.8M-91.5% | -$117.9M-44.4% | -$81.7M-76.5% | -$46.3M |
| Investing Cash Flow | -$415.6M | $89.8M+125.0% | -$358.9M-33.8% | -$268.3M-332.1% | -$62.1M |
| Financing Cash Flow | $761.5M | $762.5M+48.0% | $515.3M+14.1% | $451.5M+1456.3% | $29.0M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
GPCR Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|
| Return on Equity | -9.3%+4.9pp | -14.2%+5.6pp | -19.8% | N/A |
| Return on Assets | -8.9%+4.7pp | -13.6%+5.0pp | -18.6%+33.9pp | -52.4% |
| Current Ratio | 24.81+0.1x | 24.74+5.6x | 19.14+12.0x | 7.16 |
| Debt-to-Equity | 0.040.0x | 0.040.0x | 0.06 | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Structure Therapeutics Inc ADR Ranks
Frequently Asked Questions
Is Structure Therapeutics Inc ADR profitable?
No, Structure Therapeutics Inc ADR (GPCR) reported a net income of -$141.2M in fiscal year 2025.
What is Structure Therapeutics Inc ADR's EBITDA?
Structure Therapeutics Inc ADR (GPCR) had EBITDA of -$175.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Structure Therapeutics Inc ADR's return on equity (ROE)?
Structure Therapeutics Inc ADR (GPCR) has a return on equity of -9.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Structure Therapeutics Inc ADR's free cash flow?
Structure Therapeutics Inc ADR (GPCR) recorded an outflow of $225.8M in free cash flow during fiscal year 2025. This represents a -91.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Structure Therapeutics Inc ADR's operating cash flow?
Structure Therapeutics Inc ADR (GPCR) recorded an outflow of $222.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Structure Therapeutics Inc ADR's total assets?
Structure Therapeutics Inc ADR (GPCR) had $1.6B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Structure Therapeutics Inc ADR's capital expenditures?
Structure Therapeutics Inc ADR (GPCR) invested $3.6M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Structure Therapeutics Inc ADR spend on research and development?
Structure Therapeutics Inc ADR (GPCR) invested $225.3M in research and development during fiscal year 2025.
What is Structure Therapeutics Inc ADR's current ratio?
Structure Therapeutics Inc ADR (GPCR) had a current ratio of 24.81 as of fiscal year 2025, which is generally considered healthy.
What is Structure Therapeutics Inc ADR's debt-to-equity ratio?
Structure Therapeutics Inc ADR (GPCR) had a debt-to-equity ratio of 0.04 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Structure Therapeutics Inc ADR's return on assets (ROA)?
Structure Therapeutics Inc ADR (GPCR) had a return on assets of -8.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Structure Therapeutics Inc ADR's cash runway?
Based on fiscal year 2025 data, Structure Therapeutics Inc ADR (GPCR) had $799.6M in cash against an annual operating cash burn of $222.2M. This gives an estimated cash runway of approximately 43 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Structure Therapeutics Inc ADR's Piotroski F-Score?
Structure Therapeutics Inc ADR (GPCR) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Structure Therapeutics Inc ADR's earnings high quality?
Structure Therapeutics Inc ADR (GPCR) reported a net loss of $141.2M while operations used $222.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.